Diarylamide Compound and Application Thereof

A method for treating or preventing diseases related to a urea transporter inhibitor, comprising administering a therapeutically effective amount of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof,

• wherein,
• ring A and ring B are each independently a 5- to 6-membered heteroaryl group or a 5- to 6-membered aryl group;
• ring A and ring B are optionally substituted with R1 and R2 respectively:
• R1 is selected from the group consisting of nitro, halogen, alkyl, alkylcarbonyl, alkylcarbonylamino, alkylsulfonyl and pyrido groups;
• R2 is selected from the group consisting of halogen, hydroxy, amino, cyano, alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkoxy, alkylcarbonyl, alkoxycarbonyl, pyrido, alkylcarbonylamino optionally substituted with R5, heterocyclic or cyclic group optionally substituted with R5, heteroarylcarbonylamino optionally substituted with R5, N-alkylamino, N,N-di(alkyl)amino, and aminocarbonyl substituted with R3 and R4;
• wherein, R3 and R4 are each independently selected from the group consisting of H, hydroxyl, alkyl, heterocyclic or cyclic group optionally substituted with R5, heterocyclic or cyclic alkyl optionally substituted with R5, heteroaryl or aryl alkyl optionally substituted with R5, N-(alkyl)aminoalkyl, and N,N-di(alkyl)aminoalkyl;
• and
• R5 is selected from the group consisting of alkyl, nitro, alkylcarbonylamino, N-(alkyl)amino, N,N-di(alkyl)amino, N,N-di(alkyl)aminoalkylamino, and heterocyclic or cyclic group.

A diarylamide compound, or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of the following compounds, or the pharmaceutically acceptable salts thereof:

• (15)N-(pyridazin-3-yl)-5-nitrofuran-2-carboxamide;
• (17)N-(thiophen-3-yl)-5-nitrofuran-2-carboxamide;
• (25)N-(4-acetamidophenyl)-5-methylsulfonylfuran-2-carboxamide;
• (26)N-(2-acetamidophenyl)-5-nitrofuran-2-carboxamide;
• (51)N-(4-aminomethylphenyl)-5-nitrofuran-2-carboxamide;
• (53)N-3-(methylcarbamoyl)phenyl)-5-nitrofuran-2-carboxamide;
• (55)N-(3-(ethylcarbamoyl)phenyl)-5-nitrofuran-2-carboxamide;
• (56)N-(3-(isopropylcarbamoyl)phenyl)-5-nitrofuran-2-carboxamide;
• (57)N-(3-(isobutylcarbamoyl)phenyl)-5-nitrofuran-2-carboxamide;
• (58)N-(3-(cyclohexylcarbamoyl)phenyl)-5-nitrofuran-2-carboxamide;
• (59)N-(3-(benzylcarbamoyl)phenyl)-5-nitrofuran-2-carboxamide;
• (60)N-(3-((2-dimethylaminoethyl)carbamoyl)phenyl)-5-nitrofuran-2-carboxamide;
• (61)N-(3-((2-morpholinylethyl)carbamoyl)phenyl)-5-nitrofuran-2-carboxamide;
• (62)N-(3-((3-morpholinylpropyl)carbamoyl)phenyl)-5-nitrofuran-2-carboxamide;
• (63)N-(4-methyl-3-methylcarbamoylphenyl)-5-nitrofuran-2-carboxamide;
• (64)N-(5-methyl-3-methylcarbamoylphenyl)-5-nitrofuran-2-carboxamide;
• (65)N-(4-fluoro-3-methylcarbomoylphenyl)-5-nitrofuran-2-carboxamide;
• (66)N-(5-fluoro-3-methylcarbamoylphenyl)-5-nitrofuran-2-carboxamide;
• (67)N-(4-hydroxy-3-methylcarbamoylphenyl)-5-nitrofuran-2-carboxamide;
• (68) N1,N3-dimethyl-5-(5-nitrofuran-2-carboxamido)isophthalamide;
• (69)N-(2-methyl-1,3-dihydro-1,3-dioxo-2H-isoindol-5-yl)-5-nitrofuran-2-carboxamide;
• (70)N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide;
• (71)N-(4-(2-dimethylamino)acetamidophenyl)-5-nitrofuran-2-carboxamide;
• (72)N-(4-(2-morpholinyl)acetamidophenyl)-5-nitrofuran-2-carboxamide;
• (73)N-(4-(3-dimethylamino)propionamidophenyl)-5-nitrofuran-2-carboxamide;
• (74)N-(4-((2-dimethylamino)ethylamino)acetamidophenyl)-5-nitrofuran-2-carboxamide;
• (75) ethyl 2-acetamido-5-(5-nitrofuran-2-carboxamide)benzoate;
• (76) ethyl 5-(5-nitrofuran-2-carboxamide)-1H-pyrazole-4-carboxylate;
• (77) ethyl 5-(5-nitrofuran-2-carboxamide)-1H-pyrazole-3-carboxylate;
• and
• (78) 3-(5-acetyl-2-furoyl)carbamamide.